Hot on the heels of a US Food and Drug Administration filing for its MSB11456 tocilizumab biosimilar candidate, Fresenius Kabi has announced that the European Medicines Agency has also accepted a filing for its proposed version of RoActemra.
Just weeks ago, the German firm – which is increasingly focusing attention and financial firepower on its biosimilars business, including...






